Onco-Innovations sets out updates from the past months

Executive Summary

• Onco-Innovations Ltd. provided a strategic update following CEO Thomas O'Shaughnessy’s appearance on Cboe Canada’s Investor Spotlight, highlighting recent milestones and future growth plans.
• The company outlined a strategic pivot toward clinical development, with plans to initiate a Phase 1 clinical trial in 2026, marking a transition from preclinical research to clinical translation.
• Onco-Innovations announced intentions to pursue a U.S. stock exchange cross-listing in 2026 to enhance shareholder value, expand access to institutional and retail investors, and strengthen engagement with the North American R&D community.

Key Details

• Recent Milestones (2025):
  • February 2025: Acquired Inka Health AI.
  • May 2025: Partnered with Dalton Pharma Services.
  • June 2025: Entered into continued collaboration with the University of Alberta and the Cross Cancer Institute.
  • July 2025: Signed an agreement with Nucro-Technics.
  • Undated: Entered into a start-up agreement with Avance Clinical Pty. Ltd.
• Strategic Goals:
  • Clinical Trials: Laying groundwork for a Phase 1 clinical trial in 2026 to move from preclinical testing to clinical validation.
  • U.S. Expansion: Pursuing a U.S. stock exchange cross-listing in 2026 to broaden investor base and R&D engagement.
  • Listing Change: Previously moved stock listing to the Cboe Canada Market.
• Company Focus: Specializing in oncology with an exclusive worldwide license to patented technology targeting solid tumors.

Notable Quotes

• "The groundwork we have laid over the past several months has positioned us to move decisively into clinical development. We are now entering an exciting phase where our focus evolves from preclinical success to preparing for clinical validation. Our near-term priorities include completing the necessary steps for our first-in-human trial and advancing our U.S. strategy, both of which will be key drivers of our next stage of growth," stated Mr. O'Shaughnessy.